Skip to main content
NewslettersWatchlist

Cytomx Thera(CTMX-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low1.9300
Day High2.0100
Open:1.9800
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Newswire.ca
Biotech Companies Making Strides in Pancreatic Cancer Treatment and Early Detection
BayStreet.ca
Biotech Innovations Drive Hope in Global Fight Against Pancreatic Cancer
Barchart
Stocks Set to Open Higher as Investors Await More Corporate Earnings and Fed Speak
PR Newswire
Evolution of Oncology Treatments Giving New Hope to Those Diagnosed with Breast Cancer
BayStreet.ca
Breast Cancer Treatment Options Evolved Over the Last 12 Months, Bringing More Hope for 2023
Barchart
Pre-Market Brief: Stocks Move Higher Ahead Of Key U.S. Payrolls Data
Spotlight Growth
CytomX Therapeutics (NASDAQ: CTMX) and Regeneron (NASDAQ: REGN) Enter into Strategic Collaboration to Develop Bispecific Therapies to Treat Cancer
Motley Fool
CytomX Therapeutics (CTMX) Q2 2022 Earnings Call Transcript
Globe Newswire
CytomX Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
Globe Newswire
CytomX Therapeutics to Present at Upcoming Virtual August Investor Conferences
TipRanks
CytomX Therapeutics (CTMX) Receives a Hold from Mizuho Securities
Globe Newswire
CytomX Therapeutics Provides Strategic Update
Globe Newswire
CytomX Therapeutics Announces Phase 2 Results for Praluzatamab Ravtansine in Breast Cancer
Globe Newswire
CytomX Therapeutics Announces New Employment Inducement Grants
Globe Newswire
CytomX Therapeutics to Present at Jefferies 2022 Global Healthcare Conference
Globe Newswire
CytomX Therapeutics Announces First Patient Dosed with CX-904 in Phase 1 Study in Patients with Advanced Solid Tumors
Motley Fool
CytomX Therapeutics (CTMX) Q1 2022 Earnings Call Transcript
Globe Newswire
CytomX Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
Globe Newswire
CytomX Therapeutics to Report First Quarter 2022 Financial Results on May 5, 2022
Globe Newswire
CytomX Therapeutics Announces Retirement of John A. Scarlett, M.D. from Board of Directors
Globe Newswire
CytomX Therapeutics Announces Retirement of Frederick W. Gluck from Board of Directors
Motley Fool
CytomX Therapeutics (CTMX) Q4 2021 Earnings Call Transcript
Globe Newswire
CytomX Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Business Update
Globe Newswire
CytomX Therapeutics Announces New Employment Inducement Grants
Globe Newswire
CytomX Therapeutics Announces Promotion of Amy C. Peterson, M.D. to President and Chief Operating Officer
Globe Newswire
CytomX Therapeutics Announces FDA Clearance of Investigational New Drug Application for CX-904 for the Treatment of Advanced Solid Tumors
Globe Newswire
CytomX Therapeutics Announces Preliminary Results for Ongoing Phase 2 Expansion Study of CX-2029, a First-in-Class Antibody-Drug Conjugate Candidate Targeting the Transferrin Receptor, CD71
Globe Newswire
CytomX Therapeutics to Present at Upcoming November Investor Conferences
Globe Newswire
CytomX Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update
Globe NewsWire
CytomX Therapeutics Announces New Employment Inducement Grants
Globe NewsWire
CytomX Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference
Globe NewsWire
CytomX Therapeutics Announces New Employment Inducement Grants

Profile

CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.